| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
Kira8 Hydrochloride manufacturers
|
| | Kira8 Hydrochloride Basic information |
| Product Name: | Kira8 Hydrochloride | | Synonyms: | KIRA8 HYDROCHLORIDE (AMG-18 HYDROCHLORIDE);Kira8 Hydrochloride;AMG-18 Hydrochloride;(S)-2-Chloro-N-(6-methyl-5-((3-(2-(piperidin-3-ylamino)pyrimidin-4-yl)pyridin-2-yl)oxy)naphthalen-1-yl)benzenesulfonamide hydrochloride;Kira8 Hydrochloride,Kira-8 Hydrochloride | | CAS: | 2250019-92-0 | | MF: | C31H29ClN6O3S.ClH | | MW: | 637.58 | | EINECS: | | | Product Categories: | | | Mol File: | 2250019-92-0.mol |  |
| | Kira8 Hydrochloride Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | Kira8 Hydrochloride Usage And Synthesis |
| Uses | Kira8 Hydrochloride (AMG-18 Hydrochloride) is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity with an IC50 of 5.9 nM[1]. | | in vivo | Male Ins2+/Akita mice are injected i.p. with KIRA8 (50 mg/kg; daily; for 35 days), significant reduction of hyperglycemia become apparent over several weeks[1].
One week treatment of pre-diabetic NODs mice with Kira8 (50 mg/kg; i.p.; once a day) leads to significant reductions in islet XBP1 splicing and TXNIP mRNAs, and preserves Ins1/Ins2, BiP and MANF mRNAs[1]. | Animal Model: | Male Ins2+/Akita mice[1] | | Dosage: | 50 mg/kg | | Administration: | Injected i.p.; daily; for 35 days | | Result: | Significant reduction of hyperglycemia became apparent over several weeks. |
| | storage | Store at -20°C | | References | [1] Morita S, et al. Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes. Cell Metab. 2017 Apr 4;25(4):883-897.e8. DOI:10.1016/j.cmet.2017.03.018 |
| | Kira8 Hydrochloride Preparation Products And Raw materials |
|